Sangamo Therapeutics (SGMO) News Today $0.86 +0.19 (+28.15%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 28 at 5:58 PM | marketbeat.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Short Interest UpdateSangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) saw a significant drop in short interest in July. As of July 15th, there was short interest totalling 12,730,000 shares, a drop of 17.9% from the June 30th total of 15,510,000 shares. Based on an average trading volume of 6,250,000 shares, the days-to-cover ratio is currently 2.0 days.July 28 at 1:17 AM | marketbeat.comStockNews.com Begins Coverage on Sangamo Therapeutics (NASDAQ:SGMO)StockNews.com started coverage on Sangamo Therapeutics in a research note on Sunday. They set a "sell" rating on the stock.July 25 at 6:36 AM | americanbankingnews.comSangamo Therapeutics (NASDAQ:SGMO) Earns Buy Rating from HC WainwrightJuly 24, 2024 | investorplace.comWhy Is Sangamo Therapeutics (SGMO) Stock Up 40% Today?July 24, 2024 | marketbeat.comSangamo Therapeutics' (SGMO) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $5.00 price objective on shares of Sangamo Therapeutics in a research note on Wednesday.July 21, 2024 | americanbankingnews.comSangamo Therapeutics (NASDAQ:SGMO) Receives New Coverage from Analysts at StockNews.comJuly 20, 2024 | marketbeat.comSangamo Therapeutics (NASDAQ:SGMO) Now Covered by StockNews.comStockNews.com assumed coverage on Sangamo Therapeutics in a research note on Saturday. They issued a "sell" rating on the stock.July 3, 2024 | marketbeat.comWasatch Advisors LP Buys 7,734,400 Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO)Wasatch Advisors LP increased its stake in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) by 62.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,132,324 shares of the biopharmaceutical compJune 12, 2024 | marketbeat.comWasatch Advisors LP Lowers Holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)Wasatch Advisors LP reduced its position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) by 31.1% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 12,397,924 shares of the biopharmaceutical company's stock after selling 5,588,857 shares during the qJune 12, 2024 | marketbeat.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Consensus Rating of "Moderate Buy" from BrokeragesSangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) has received a consensus rating of "Moderate Buy" from the six brokerages that are presently covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and three have issued a buMay 29, 2024 | finance.yahoo.comWe Think Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation Package Needs To Be Put Under A MicroscopeMay 17, 2024 | marketbeat.comQ2 2024 EPS Estimates for Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Decreased by HC WainwrightSangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - Investment analysts at HC Wainwright decreased their Q2 2024 earnings per share (EPS) estimates for Sangamo Therapeutics in a report issued on Wednesday, May 15th. HC Wainwright analyst P. Trucchio now anticipates that the biopharmaceuticalMay 16, 2024 | marketbeat.comHC Wainwright Weighs in on Sangamo Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:SGMO)Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - HC Wainwright issued their Q1 2025 earnings estimates for Sangamo Therapeutics in a research report issued to clients and investors on Wednesday, May 15th. HC Wainwright analyst P. Trucchio expects that the biopharmaceutical company will eaMay 12, 2024 | finance.yahoo.comUS$3.50 - That's What Analysts Think Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Is Worth After These ResultsMay 11, 2024 | finance.yahoo.comSangamo Therapeutics First Quarter 2024 Earnings: US$0.27 loss per share (vs US$0.13 profit in 1Q 2023)May 10, 2024 | marketbeat.comSangamo Therapeutics (NASDAQ:SGMO) Issues Earnings ResultsSangamo Therapeutics (NASDAQ:SGMO - Get Free Report) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.05). Sangamo Therapeutics had a negative return on equity of 82.17% and a negative net margin of 146.30%. The business had revenue of $0.48 million during the quarter, compared to analysts' expectations of $8.51 million. During the same period in the previous year, the business earned $0.12 EPS.May 10, 2024 | finance.yahoo.comSangamo Therapeutics Reports Q1 2024 Results: A Deep Dive into Financials and Strategic HighlightsMay 9, 2024 | msn.comSGMO Stock Earnings: Sangamo Therapeutics Misses EPS, Misses Revenue for Q1 2024May 9, 2024 | businesswire.comSangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial ResultsMay 9, 2024 | finanznachrichten.deSangamo Therapeutics, Inc.: Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome EditingMay 9, 2024 | finance.yahoo.comSangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome EditingMay 8, 2024 | markets.businessinsider.comSangamo Therapeutics is about to announce its earnings — here's what Wall Street expectsMay 3, 2024 | marketbeat.comSangamo Therapeutics (SGMO) Scheduled to Post Quarterly Earnings on ThursdaySangamo Therapeutics (NASDAQ:SGMO) will be releasing earnings after the market closes on Thursday, May 9, Zacks reports.May 2, 2024 | businesswire.comSangamo Therapeutics Announces First Quarter 2024 Conference Call and WebcastApril 30, 2024 | wsj.comSangamo Therapeutics Inc.April 23, 2024 | marketbeat.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Consensus Recommendation of "Hold" by BrokeragesShares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) have received a consensus recommendation of "Hold" from the seven analysts that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have given a hold rApril 22, 2024 | businesswire.comSangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)April 22, 2024 | marketbeat.comStock Traders Purchase Large Volume of Sangamo Therapeutics Call Options (NASDAQ:SGMO)Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) saw some unusual options trading activity on Monday. Investors bought 11,259 call options on the stock. This represents an increase of approximately 2,053% compared to the typical volume of 523 call options.April 2, 2024 | msn.comBiotech Roundtable: Who will bring the next CRISPR drug to market?March 29, 2024 | marketbeat.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Consensus Recommendation of "Hold" from BrokeragesShares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) have received a consensus recommendation of "Hold" from the seven ratings firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating anMarch 29, 2024 | marketbeat.comSangamo Therapeutics (NASDAQ:SGMO) Share Price Passes Above 200-Day Moving Average of $0.62Sangamo Therapeutics (NASDAQ:SGMO) Stock Price Crosses Above 200-Day Moving Average of $0.62March 25, 2024 | finance.yahoo.comWhat You Need To Know About The Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analyst Downgrade TodayMarch 21, 2024 | marketbeat.comQ1 2024 Earnings Estimate for Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Issued By HC WainwrightSangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - Investment analysts at HC Wainwright lowered their Q1 2024 earnings estimates for shares of Sangamo Therapeutics in a research note issued on Tuesday, March 19th. HC Wainwright analyst P. Trucchio now forecasts that the biopharmaceutical coMarch 19, 2024 | money.usnews.comSangamo Therapeutics IncMarch 19, 2024 | marketbeat.comSangamo Therapeutics (NASDAQ:SGMO) Given "Buy" Rating at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $5.00 price target (up from $3.00) on shares of Sangamo Therapeutics in a report on Tuesday.March 18, 2024 | marketbeat.comSangamo Therapeutics' (SGMO) Sector Perform Rating Reaffirmed at Royal Bank of CanadaRoyal Bank of Canada restated a "sector perform" rating and issued a $2.00 target price on shares of Sangamo Therapeutics in a research note on Thursday.March 18, 2024 | marketbeat.comQ1 2024 Earnings Estimate for Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Issued By WedbushSangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - Research analysts at Wedbush issued their Q1 2024 EPS estimates for Sangamo Therapeutics in a research note issued to investors on Thursday, March 14th. Wedbush analyst A. Argyrides anticipates that the biopharmaceutical company will post eMarch 16, 2024 | ca.finance.yahoo.comSGMO Apr 2024 1.500 putMarch 16, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Veradigm (OtherMDRX), ADC Therapeutics (ADCT) and Sangamo Biosciences (SGMO)March 16, 2024 | finance.yahoo.comSGMO Apr 2024 1.500 callMarch 15, 2024 | finance.yahoo.comSGMO Apr 2024 3.000 callMarch 14, 2024 | finance.yahoo.comSangamo Therapeutics Full Year 2023 Earnings: Misses ExpectationsMarch 13, 2024 | markets.businessinsider.comSangamo Biosciences’ Breakthrough Capsid Technology Spurs Buy RatingMarch 13, 2024 | markets.businessinsider.com4 Analysts Assess Sangamo Therapeutics: What You Need To KnowMarch 13, 2024 | businesswire.comSangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsMarch 12, 2024 | businesswire.comSangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and WebcastMarch 1, 2024 | finance.yahoo.comSangamo Therapeutics, Inc. (SGMO)February 23, 2024 | investing.comSangamo Therapeutics (SGMO) Earnings Dates & ReportsFebruary 17, 2024 | marketbeat.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Sees Significant Growth in Short InterestSangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) was the target of a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 9,980,000 shares, a growth of 9.0% from the January 15th total of 9,160,000 shares. Based on an average trading volume of 1,650,000 shares, the short-interest ratio is currently 6.0 days.February 13, 2024 | markets.businessinsider.comSangamo Biosciences: Hold Rating Amid Regulatory Progress and Financial Uncertainties Get Sangamo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter. Email Address top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall. Click here now for the full details of this stock that’s set to rocket in the AI revolution… SGMO Media Mentions By Week SGMO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SGMO News Sentiment▼0.430.66▲Average Medical News Sentiment SGMO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SGMO Articles This Week▼71▲SGMO Articles Average Week Get Sangamo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CLLS News ATRA News BLUE News ADAP News AGEN News VNDA News XOMA News CDXS News RIGL News ACHV News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SGMO) was last updated on 7/28/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredUrgent alert: open this for a huge profit potentialThis groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sangamo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sangamo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.